Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nurix Therapeutics (NRIX) Profit After Tax (2019 - 2025)

Nurix Therapeutics (NRIX) has disclosed Profit After Tax for 7 consecutive years, with -$78.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Profit After Tax fell 33.6% to -$78.2 million in Q4 2025 year-over-year; TTM through Nov 2025 was -$264.5 million, a 36.62% decrease, with the full-year FY2025 number at -$264.5 million, down 36.62% from a year prior.
  • Profit After Tax was -$78.2 million for Q4 2025 at Nurix Therapeutics, up from -$86.4 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of -$24.3 million in Q1 2021 to a low of -$86.4 million in Q3 2025.
  • A 5-year average of -$45.0 million and a median of -$43.0 million in 2022 define the central range for Profit After Tax.
  • Peak YoY movement for Profit After Tax: tumbled 448.05% in 2021, then surged 46.53% in 2023.
  • Nurix Therapeutics' Profit After Tax stood at -$37.7 million in 2021, then decreased by 23.91% to -$46.7 million in 2022, then increased by 10.19% to -$42.0 million in 2023, then crashed by 39.55% to -$58.5 million in 2024, then plummeted by 33.6% to -$78.2 million in 2025.
  • Per Business Quant, the three most recent readings for NRIX's Profit After Tax are -$78.2 million (Q4 2025), -$86.4 million (Q3 2025), and -$43.5 million (Q2 2025).